

Michael Schweitz, MD
President

Michael Stevens, MD
Vice President

Mark Box, MD
Secretary

Gregory Schimizzi, MD
Treasurer

Jacob Aelion, MD
Director

Aaron Broadwell, MD
Director

Gary R. Feldman, MD
Director

Madelaine Feldman, MD
Director

Philippe Saxe, MD
Director

Joshua Stolow, MD
Director

Robert Sylvester, MD
Director

Two Woodfield Lake
1100 E Woodfield Road, Suite 350
Schaumburg, IL 60173-5116
Phone: (847) 517-7225 | (847) 517-7229
Email: csro@wjweiser.com | Website: www.csro.info

February 26, 2015

Maryland House Health & Government Operations Committee
House Office Building,
6 Bladen St.
Annapolis, Maryland 21401

Re: Support of HB 733 (Cullison) – Pharmacists – Substitution and Dispensing – Interchangeable Biological Products

Dear Members of the House Health & Government Operations Committee:

The Coalition of State Rheumatology Organizations (CSRO) is a national organization composed of 30 state and regional professional rheumatology societies formed in order to advocate and ensure excellence and access to the highest quality care for patients with rheumatologic and musculoskeletal disease.

Rheumatologists are on the forefront of utilizing the dramatic long-term, life-changing clinical improvements that biological products have on Americans. Biological products available for the treatment of rheumatoid arthritis and other autoimmune diseases have had a significant impact on improving our patients' quality of life, preventing disability, and lowering mortality.

As the House Health & Government Operations Committee considers HB 733 (Cullison), CSRO wishes to convey its support for the legislation.

This bill provides important pathways for medication access, while requiring much needed patient safety rules for dispensing pharmacists to notify physicians of biosimilar substations within 10 days. Requiring notification within 10 days provides physicians a consistent window to understand and counter any adverse effects of medications.

With upcoming FDA approval expected this year, interchangeable biological products will continue to be an important issue for rheumatology patients. CSRO supports safe introduction of biosimilars into the practice of medicine and urges passage of HB 733.

Sincerely,



Michael Schweitz, MD
President
Coalition of State Rheumatology Organizations